News Releases

Advanced Search
  • Mar 27, 2019
    RegeneRx to Present at 2019 Spring Investor Summit
    Presentation on Tuesday, April 2, 2019 at 9:00 a.m. ET

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...

  • Mar 26, 2019
    RegeneRx and Lee's Pharm to Accelerate RGN-259 Development in China
    Lee's Pharm Participates in Recent RegeneRx Financing

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee's...

  • Mar 21, 2019
    RegeneRx Announces New Board Member

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the...

  • Feb 27, 2019
    RegeneRx Closes $1.3 Million Convertible Debt Financing
    Funding for Operations Over Next 12 Months During Phase 3 Ophthalmic Trials

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...

  • Feb 12, 2019
    RegeneRx's U.S. Joint Venture Initiates Key Phase 3 Dry Eye Clinical Trial with RGN-259

    RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that...

Show 5102550100 per page